Reuters Reuters
1 May, 2021, 2:09 am
FILE PHOTO: A nurse holds a syringe containing a coronavirus disease (COVID-19) vaccine made by the Beijing Institute of Biological Products, a unit of Sinopharm subsidiary China National Biotec Group (CNBG), at a vaccination center during a government-organized visit, in Beijing, China, April 15, 2021. REUTERS/Thomas Peter/File Photo
JAKARTA (Reuters) – Indonesia’s drug regulator on Friday approved the COVID-19 vaccine of China’s Sinopharm, which it will use in a private immunisation scheme where companies buy government-procured vaccines to inoculate their staff.
After Sinovac Biotech and AstraZeneca, Sinopharm is the third company to have its vaccine approved by Indonesia, which is seeking to inoculate 181.5 million people by January 2022.
Friday, 30 Apr 2021 03:25 PM MYT
After Sinovac Biotech and AstraZeneca, Sinopharm is the third company to have its vaccine approved by Indonesia, which is seeking to inoculate 181.5 million people by January 2022. Reuters pic
Subscribe to our Telegram channel for the latest updates on news you need to know.
JAKARTA, April 30 ― Indonesia s drug regulator today approved the Covid-19 vaccine of China s Sinopharm, which it will use in a private immunisation scheme where companies buy government-procured vaccines to inoculate their staff.
After Sinovac Biotech and AstraZeneca, Sinopharm is the third company to have its vaccine approved by Indonesia, which is seeking to inoculate 181.5 million people by January 2022.